-
Drinking water screening value for diuron
A drinking water screening value of 0.03 mg/L (30 µg/L) is established for diuron. -
Guidelines for Canadian Drinking Water Quality: Guideline Technical Document...
The production of ammonia is a normal part of metabolism, and levels occurring in the human body from metabolic processes generally exceed concentrations found in drinking... -
Drug and vaccine authorizations for COVID-19: Overview
Health Canada scientific reviewers evaluate data to assess the potential benefits and risks of a drug or vaccine. They also review the information that will be provided to... -
Improving the regulatory review of drugs and devices: Improving access to...
The updated regulations will help drug makers understand what information should be included in their drug submissions. This will help with product approval and availability. -
Protecting your health from climate change impacts
You can prepare for the hazardous events and conditions that climate change can bring. -
2025 Dose Data from the Fixed Point Surveillance Network
The Fixed Point Surveillance (FPS) network monitors public radiation dose due to radioactive materials in the atmosphere. The FPS network is used primarily to measure the... -
Natural Health Product Licence Application Form User Manual
The Electronic Product Licence Application (ePLA) form is for Natural Health Product Licence Applications and for post-licence changes. The ePLA is designed to be completed on... -
Industry Guide for the labelling of cosmetics
This guide is designed to assist in the preparation of labels that comply with Canadian regulatory requirements for cosmetics. -
Vaping Compliance and Enforcement Data Summary (manufacturer inspections)
This dataset provides a summary of vaping compliance and enforcement inspections conducted at manufacturers by Health Canada. The manufacturer data set includes information on... -
Guidance for market authorization requirements for COVID-19 vaccines:...
Modified requirements for COVID-19 drugs allow for the filing of rolling submissions (section C.08.002(2.3) of Canada's Food and Drug Regulations). Before filing a submission... -
Substance-related poisonings and homelessness in Canada: a descriptive...
The Public Health Agency of Canada (PHAC), in collaboration with the provincial and territorial (PT) offices of Chief Coroners and Chief Medical Examiners, PT public health and... -
Food-Related Health Risk Assessment
It is within the mandate of Health Canada's Food Directorate to conduct food-related health risk assessments. This involves determining if the presence of a certain substance or... -
Notice: Prescription Drug List (PDL): Multiple Additions (2021-09-10)
The purpose of this Notice of Amendment is to notify about the additions of: Elexacaftor, Inclisiran, Ospemifene, Pralsetinib and Tafasitamab to the Prescription Drug List (PDL)... -
Notice: Proposed Modification to Bioequivalence Standards for Multiphasic...
This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (i.e., new drug and abbreviated new drug submissions), of... -
Cannabis key investors record keeping: Cultivation, processing and sale for...
Information about key investors in the cannabis sector: who needs to report, identifying key investors, requirements for applicants and licence holders. -
Canada-Prince Edward Island Bilateral Agreement for Pan-Canadian Virtual...
Canada and Prince Edward Island agree that immediate action and collaboration was and continues to be needed among governments to expand virtual care services to support... -
About the process: Cannabis security clearances
The security clearance (SC) process assesses if an applicant could pose an unacceptable risk to public health or public safety. This includes the risk of cannabis being diverted... -
Prescription management by pharmacists with controlled substances under the...
Health Canada's interpretation of controlled substances prescribing activities pharmacists can perform under the Controlled Drugs and Substances Act. -
Summary Safety Review - Strontium - Risk of Heart and Circulatory Side Effects
The European Medicines Agency completed a safety review of strontium ranelate, a drug available by prescription only in Europe at a dose of 680 mg per day and used to treat... -
Proposed Re-evaluation Decision PRVD2020-11, (S)-kinoprene and its...
This document presents the proposed regulatory decision for the re-evaluation of (S)-kinoprene
Vous pouvez également accéder à ce catalogue en utilisant l'API (cf. Documentation de l'API).